Literature DB >> 8199978

[Severe rhabdomyolysis in a patient receiving lovastatin, danazol, and doxycycline].

M Dallaire1, M Chamberland.   

Abstract

Combinations of lovastatin and other drugs have been reported to cause rhabdomyolysis and myoglobinuria. The authors report such a case in a 72-year-old man who had been receiving atenolol, acetylsalicylic acid (ASA), dipyridamole, lovastatin, danazol, prednisone and doxycycline. The ASA, lovastatin and danazol were discontinued. The symptoms resolved, and laboratory test results were normal within 2 weeks. Lovastatin was strongly suspected; danazol was the most likely potentiator by diminishing the metabolism of lovastatin and its metabolites in the liver or by having a direct toxic effect on the muscles.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8199978      PMCID: PMC1337012     

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  14 in total

1.  Lovastatin and rhabdomyolysis.

Authors:  J Z Ayanian; C S Fuchs; R M Stone
Journal:  Ann Intern Med       Date:  1988-10-15       Impact factor: 25.391

2.  Myolysis and acute renal failure in a heart-transplant recipient receiving lovastatin.

Authors:  D J Norman; D R Illingworth; J Munson; J Hosenpud
Journal:  N Engl J Med       Date:  1988-01-07       Impact factor: 91.245

3.  Rhabdomyolysis in patients receiving lovastatin after cardiac transplantation.

Authors:  C East; P A Alivizatos; S M Grundy; P H Jones; J A Farmer
Journal:  N Engl J Med       Date:  1988-01-07       Impact factor: 91.245

4.  Myalgia and elevated creatine phosphokinase with Danazol in hereditary angioedema.

Authors:  W B Spaulding
Journal:  Ann Intern Med       Date:  1979-05       Impact factor: 25.391

5.  Effect of danazol on cyclosporine pharmacokinetics.

Authors:  B Koneru; C Hartner; S Iwatsuki; T E Starzl
Journal:  Transplantation       Date:  1988-05       Impact factor: 4.939

Review 6.  Lovastatin. A preliminary review of its pharmacodynamic properties and therapeutic use in hyperlipidaemia.

Authors:  J M Henwood; R C Heel
Journal:  Drugs       Date:  1988-10       Impact factor: 9.546

7.  Actions of danazol in vivo on cytochrome P-450 and steroidogenic enzymes in rat testis and liver microsomal preparations.

Authors:  G Betz; H H Miller; D B Hales
Journal:  Am J Obstet Gynecol       Date:  1981-12-15       Impact factor: 8.661

Review 8.  Lovastatin-induced rhabdomyolysis in the absence of concomitant drugs.

Authors:  C S Wallace; B A Mueller
Journal:  Ann Pharmacother       Date:  1992-02       Impact factor: 3.154

Review 9.  Efficacy and long-term adverse effect pattern of lovastatin.

Authors:  J A Tobert
Journal:  Am J Cardiol       Date:  1988-11-11       Impact factor: 2.778

10.  Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients.

Authors:  C L Corpier; P H Jones; W N Suki; E D Lederer; M A Quinones; S W Schmidt; J B Young
Journal:  JAMA       Date:  1988-07-08       Impact factor: 56.272

View more
  1 in total

1.  Rhadbomyolysis associated with co-administration of danazol and lovastatin.

Authors:  Sahil Khanna; William C Mundell
Journal:  Br J Clin Pharmacol       Date:  2011-07       Impact factor: 4.335

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.